Immunotherapy for Prostate Cancer
Table 1. Es mated Price of Agents Approved to Treat
Prostate Cancer
Treatment Cost of treatment alone
a
Median overall survival
benefit
Sipuleucel-T $93,000 (median 3 cycles) 25.8 months vs. 21.7 months
Enzalutamide $89,952 (median of 8 cycles) 18.4 months vs. 13.6 months
Abiraterone $144,950 (median of 14 cycles) 34.7 months vs. 30.3 months
Docetaxel $25,000 (median of 10 cycles) 18.9 months vs. 16.5 months
Cabazitaxel $68,751 (median of 6 cycles) 15.1 months vs. 12.7 months
Radium-223 $155,048 (median of 6 injec ons) 14.9 months vs. 11.3 months
a
As based on es mates of average wholesale drug prices retrieved from UptoDate.com.
Accessed Nov. 17, 2016
Table 2. Phase II Sipuleucel-T Combina on Studies
Trial
Na onal clinical
trial iden fier Status
a
Provenge
followed by
docetaxel
NCT02793219
Single group assignment; Not yet recrui ng;
Expected comple on date October 2016
Sipuleucel-T
and stereotac c
abla ve body
radia on (SABR)
NCT01818986
Single group assignment; Recrui ng;
Expected comple on date April 2016
APC8015 and
bevacizumab
NCT00027599
Single group assignment; Completed
Sipuleucel-T
with or without
tasquinimod
NCT02159950
Completed
Sequencing of
sipuleucel-T and
ADT
NCT01431391
Completed
Concurrent
vs. sequen al
sipuleucel-T and
abiraterone
NCT01487863 Completed
